1 citations
,
September 2024 in “African Journal of Urology” Dutasteride is slightly better than finasteride for treating BPH but has fewer sexual side effects.
4 citations
,
February 2016 in “The Journal of urology/The journal of urology” Most care for benign prostatic hyperplasia follows guidelines, but 5-α reductase inhibitors are often used incorrectly.
January 1998 in “Dermatologic Surgery”
April 2025 in “Dermatology Practical & Conceptual” UV-enhanced trichoscopy helps diagnose hair shaft disorders like pili annulati.
January 2020 in “Medpluse International Journal of Anatomy” June 2018 in “Evidence-Based Practice” Finasteride can double the risk of sexual problems like ejaculation issues, low libido, and impotence.
2 citations
,
May 2022 in “International Journal of Impotence Research” Finasteride may be linked to Peyronie’s disease, but more research is needed.
January 2019 in “Indian Journal of Dermatology, Venereology and Leprology” November 2003 in “PubMed” May 2023 in “Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy” A new green method accurately measures finasteride and tadalafil in drugs and plasma.
March 2014 in “The Journal of Urology” Long-term treatment with finasteride or combined therapy worsens sexual function in men with urinary issues.
1 citations
,
January 2002 in “European Urology Supplements” Tamsulosin works faster, but both drugs have similar effects after 6 months.
April 2026 in “The Journal of Urology” Finasteride and dutasteride reduce semen quality, with dutasteride having a stronger negative effect.
January 2020 in “Proyecto de investigación:” Longer anogenital distance may indicate a higher chance of having polycystic ovary syndrome, and measuring this distance along with hormone levels could improve diagnosis.
137 citations
,
January 2000 in “Skin Pharmacology and Physiology” The document recommends using both clinical evaluation and various measurement methods to assess skin greasiness, considering factors like temperature and hormones.
June 2025 in “International Journal of Computational Intelligence Systems” The TPAP method effectively categorizes androgenetic alopecia patients with high accuracy, but needs real-world validation.
Researchers developed a quick and accurate method to measure hormones in urine, confirming a baldness treatment's effectiveness without altering hormone levels.
June 2024 in “International Journal of Pharmaceutical Quality Assurance” The method accurately and quickly measures silodosin and dutasteride in mixtures.
5 citations
,
October 2021 in “Journal of the American Academy of Dermatology” PRAME helps distinguish between benign and malignant skin cells in most cases.
August 2019 in “The Journal of Urology” Treatment with 5α-reductase inhibitors is linked to a delay in prostate cancer diagnosis and may affect survival rates.
February 2025 in “International Urology and Nephrology” Peripheral treatments showed some improvement in sexual dysfunction, but central symptoms remain challenging.
28 citations
,
August 2011 in “Journal of The American Academy of Dermatology” Early hair loss may indicate prostate issues.
January 2017 in “Clinical pharmacist” Long use of finasteride and dutasteride can cause long-term erection problems.
13 citations
,
September 2013 in “Steroids” The DHT immunoassay is unreliable due to high cross-reactivity with testosterone.
46 citations
,
January 2005 in “PubMed” Older men with severe symptoms and larger prostates should focus on prevention, using finasteride and alpha-blockers to manage acute urinary retention.
1 citations
,
January 2003 in “Dermatology” Finasteride's effectiveness measured by observing hair cortex changes using a cheap and easy method.
January 2025 in “International Journal of Drug Delivery Technology” A reliable method was developed to measure Finasteride and Tadalafil together, showing they degrade under certain conditions.
97 citations
,
May 2004 in “British Journal of Urology” Dual therapy with specific medications can help manage male urinary symptoms and reduce side effects.
August 2025 in “The Journal of Sexual Medicine” Finasteride, dutasteride, and silodosin have the highest risk for causing sexual dysfunction.